ID.1
Item
patients who initiated hemodialysis and expected to be on hemodialysis for at least 1 year
boolean
ID.2
Item
patients initiating hemodialysis requiring treatment (erythropoiesis stimulating agent or red blood cell transfusion) to correct the anemia of chronic kidney disease who are receiving erythropoiesis stimulating agent treatment at study entry or patients who do not require erythropoiesis stimulating agent therapy (hb within or above target range)
boolean
ID.3
Item
life expectancy should be more than 12 months
boolean
ID.4
Item
patients contraindicated to receive erythropoiesis stimulating agent therapy (including but not limited to patients who develop pure red cell aplasia following treatment with any erythropoiesis stimulating agent )
boolean
ID.5
Item
patients entering the study on any other agent to increase red blood cell mass (such as androgen therapy, or investigational agents, or other non-approved erythropoiesis stimulating agent)
boolean
ID.6
Item
patients unwilling or unable to receive erythropoiesis stimulating agent therapy to correct the anemia of chronic kidney disease
boolean
ID.7
Item
patients with uncontrolled hypertension
boolean
ID.8
Item
patients who for any reason cannot receive adequate antithrombotic treatment
boolean